LAUSR

DOI: 10.1002/cncr.32381, Published online July 10, 2019 in Wiley Online Library (wileyonlinelibrary.com) of blinatumomab (which does not include costs for hospitalization or the supportive care requirements associated with the mini-HCVD backbone or costs to administer 8 cycles of a 28-day continuous infusion). Given the small sample, lack of an appropriate randomized comparator, and many unanswered clinical questions regarding the efficacy and safety of the final protocol (9 patients), it is premature to conclude that this regimen is “a superior frontline approach for older patients with Ph [Philadelphia chromosome)-negative ALL.” In this era of high-cost anticancer medications, we must practice oncologic stewardship and design appropriate trials to answer these questions before adopting this costly approach into practice or moving the approach into younger patients.